Perioperative Complications and Myocardial Injury Risk in Arthoplasty Patients Suspected of Having Obstructive Sleep Apnea

Sponsor
University of British Columbia (Other)
Overall Status
Completed
CT.gov ID
NCT03281408
Collaborator
Vancouver Coastal Health Research Institute (Other)
100
1
10.3
9.8

Study Details

Study Description

Brief Summary

Obstructive Sleep Apnea (OSA) is a common and under-diagnosed breathing disorder characterized by recurrent partial or complete collapse of the upper airway (tongue, soft palate) during sleep. It causes recurrent episodes of asphyxia (suffocation) resulting in fragmented sleep, low blood oxygen levels (hypoxemia), and high carbon dioxide concentrations. Untreated OSA is associated with serious heart/lung and metabolic diseases including strokes, diabetes, and heart attacks.

When a patient with OSA undergoes surgery, the symptoms of OSA are exacerbated afterwards due to the effects of anesthesia and related medications such as those used for pain control. This puts patients at higher risk for complications and necessitates nursing care and monitoring that are resource intensive. In many hospitals, patients with an OSA diagnosis are monitored after surgery in "high acuity" wards where the nurse to patient ratio is higher than usual. These high acuity/monitored beds are often in high demand, and their unavailability may sometimes mean cancellation of surgery or prolonged patient stay in the Post-operative Recovery Room, further causing operating room backlog.

Another serious issue is that many patients do not know they actually have the OSA condition. It is estimated that up to 20% (1) of people in the general public have OSA and that 75% (2) of them are not diagnosed. When someone with OSA goes for surgery without previously being diagnosed, special precautions in care and monitoring may not be in place, until a complication develops. For this reason, this population - those most susceptible to have OSA, but with no previous formal testing for the condition - is the most at risk for complications, and is the target group for this trial.

We plan to identify the study population by screening for OSA using the STOP-BANG questionnaire. Those who score high on this 8 item screening test have high likelihood of actually having OSA if they were to undergo formal testing and diagnosis in a Sleep Lab.

We will identify cardio-respiratory complications by conducting a chart review and determine whether admission to a "high acuity" bed had any impact. As OSA patients are at higher risk for cardiovascular complications at baseline and around the time of surgery, blood test for troponin will be performed on post-op day 1 and 2 to investigate the rate of myocardial injury. With the rate of MINS (myocardial injury after non-cardiac surgery) reported to be 8% with almost 10% 30 day mortality (per VISION trial), this pilot project which focuses on arthroplasty patients with suspected OSA, will inform us of the arthroplasty surgery specific MINS risk for comparison.

Condition or Disease Intervention/Treatment Phase

    Study Design

    Study Type:
    Observational
    Actual Enrollment :
    100 participants
    Observational Model:
    Cohort
    Time Perspective:
    Prospective
    Official Title:
    Perioperative Obstructive Sleep Apnea Intervention Study
    Actual Study Start Date :
    Dec 4, 2017
    Actual Primary Completion Date :
    Aug 1, 2018
    Actual Study Completion Date :
    Oct 12, 2018

    Arms and Interventions

    Arm Intervention/Treatment
    Suspected OSA Patients Undergoing Knee or Hip Arthroplasty

    These 100 subjects will be cared for and monitored in hospital following current hospital protocol. No change or intervention is to be administered. Troponin testing will be done post-op with other routine blood work.

    Outcome Measures

    Primary Outcome Measures

    1. Composite Adverse Events [0-96 hours]

      The incidence of adverse events (each listed as a secondary outcome) related to OSA combined as a composite end point

    2. Troponin [Post-op Day 1]

      Testing for risk of MINS (myocardial injury after non-cardiac surgery)

    3. Troponin [Post-op Day 2]

      Testing for risk of MINS (myocardial injury after non-cardiac surgery)

    Secondary Outcome Measures

    1. Respiratory or Cardiac Arrest [0-96 hours]

      Activation of Code Blue

    2. Respiratory Therapy beyond standard nasal prong oxygen [0-96 hours]

    3. Pneumonia [0-96 hours]

      Fever with temp >=38 degree Celsius, leukocytosis and new infiltrate on CXR

    4. Naloxone Usage [0-96 hours]

      For opioid reversal

    5. Airway Intervention for any cause [0-96 hours]

      Use of nasal/oral airway or intubation, jaw thrust/chin lift

    6. Cardiac Arrhythmia [0-96 hours]

      New arrhythmia requiring treatment

    7. Cardiac ischemia or injury [0-48 hours]

      ECG changes or troponin elevation

    8. Transfer from normal ward bed to monitored bed [0-96 hours]

    9. Transfer to local tertiary hospital [0-96 hours]

    Other Outcome Measures

    1. 30 Day Mortality [30 days]

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    19 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    1. Patients undergoing elective primary or revision knee/hip replacement surgery.

    2. Patients with no previous OSA diagnosis (by polysomnography), who score >=5 on STOP-BANG OSA screening.

    Exclusion Criteria:
    1. Patients without ability to communicate in English by reading or writing.

    2. Patients with renal failure.

    3. Patients on CPAP therapy.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 UBC Hospital Vancouver British Columbia Canada

    Sponsors and Collaborators

    • University of British Columbia
    • Vancouver Coastal Health Research Institute

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Steven Lee, Clinical Assistant Professor, University of British Columbia
    ClinicalTrials.gov Identifier:
    NCT03281408
    Other Study ID Numbers:
    • H17-01022
    First Posted:
    Sep 13, 2017
    Last Update Posted:
    Mar 18, 2019
    Last Verified:
    Mar 1, 2019
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Product Manufactured in and Exported from the U.S.:
    Yes
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Mar 18, 2019